Casey M. Cosgrove, MD, discusses biomarker-guided treatment for endometrial cancer.
Casey M. Cosgrove, MD, an assistant professor in the Department of Gynecologic Oncology at The Ohio State University College of Medicine in Columbus, discusses biomarker-guided treatment for endometrial cancer.
According to Cosgrove, to take the next step in endometrial cancer, experts must learn from the successes shown in other cancer types. By using biomarkers, oncologists are informed about which treatment to use for patients, and which patients should not be treated.
Cosgrove says that the precision medicine landscape for endometrial cancer is exciting. There is a lot of ongoing research that will provide more information. This may eventually lead to oncologists taking a more individualized approach to the treatment of patient with endometrial cancer, explains Cosgrove.
The topic of biomarkers for endometrial cancer was discussed further in an interview with Targeted Oncology™ during which Cosgrove answers questions about the key targets in endometrial cancer, important clinical trials, and guideline updates that have potential to change endometrial cancer treatment in the near future. Cosgrove also discusses biomarker testing during the interview.
0:08 | With many different types of cancers, we’re starting to look at a more specialized approach as to how we can better take care of our patients. Endometrial cancer certainly has many opportunities where we can identify molecular markers or things that we can’t see under the microscope to help guide the best way to treat these patients.
0:32 | We can use biomarkers to treat patients, to guide which trial metric to use, [or] which type of treatment we want to use. But we can also use biomarkers to tell us which patients should be treated or maybe even…should not be treated. It’s an incredibly exciting area of research for endometrial cancer because it allows us to home in on their individual types of cancers and treat them with the most individualized approach.